AVIVAGEN INC ORD - VIVXF STOCK NEWS

Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) held its annual general meeting on April 19, 2023, where shareholders approved all resolutions, including the election of directors and the reappointment of McGovern Hurley LLP as auditors. Notably, Kym Anthony received 51.2% of votes, while Graham Burton and David Hankinson scored 93.4% and 94.3% respectively. The meeting marked the departure of board members Jeffrey Kraws and Aubrey Dan, with David Hankinson appointed as Chair and Kym Anthony as Vice-Chair. Avivagen focuses on developing health products for livestock and pets, leveraging its OxC-beta™ technology to enhance immune function and promote growth without antibiotics, which is available in several countries including the U.S. and Australia.

Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF), based in Ottawa, announced its unaudited financial results for Q1 2023. Reported net revenues totaled $66,039, down from $271,157 in Q1 2022. The comprehensive loss decreased to $(1,153,930) from $(1,552,852). As of January 31, 2023, the company had total assets of $568,302 and total liabilities of $7,678,343, resulting in a shareholders’ deficit of $(7,110,041). Avivagen specializes in products that enhance feed intake and immune function for livestock and animals, particularly through its OxC-beta™ technology.

Avivagen Inc. (OTCQB: VIVXF) has published a peer-reviewed paper highlighting OxBC, the active ingredient in OxC-beta™ Livestock, showcasing its potential as an antibiotic alternative in livestock feeds. The study reveals OxBC's safety and effectiveness in millions of animals across various settings. Results indicate significant economic benefits over traditional feeds, emphasizing the product's role in enhancing livestock health without contributing to antibiotic resistance. As of mid-2022, OxC-beta™ has been used in approximately 16 million piglets, 94,000 sows, 19.6 million poultry, and 12,000 dairy cows.

Avivagen Inc. (TSXV:VIV) has announced a "securities for services" agreement allowing executives to settle portions of their fees in common shares. Kym Anthony, the CEO, can receive up to $4,500 per month in shares, while Chief Scientific Officer Graham Burton can receive up to $1,600 monthly. The total issuance may reach a maximum of $10,000 monthly. The agreements are subject to approval by the TSX Venture Exchange, with share values determined based on the market price before issuance. Avivagen focuses on immune health products for livestock and companion animals.

Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) reported its unaudited financial results for Q3 2022, ending July 31. The company generated $48,606 in net revenues, a significant drop from $878,811 in Q3 2021. Comprehensive losses increased to $(1,901,453) compared to $(1,209,130) the previous year. For the nine-month period, revenues totaled $408,201, also down from $1,300,412. Total assets stood at $1,660,004 against total liabilities of $6,920,903, resulting in a shareholders' deficit of $(5,260,899). Ira Levy was appointed as interim CFO.

Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) has announced the publication of a scientific paper on the safety and uptake of its product, OxC-beta™, in the Journal of Food and Chemical Toxicology. This milestone is expected to pave the way for broader regulatory clearance and market adoption of OxC-beta in the U.S. and globally. The publication, led by Dr. Graham Burton and his team, emphasizes OxC-beta's strong safety profile, supported by ten peer-reviewed papers, and aims to improve market access and acceptance as a non-antibiotic alternative in livestock feed.

Avivagen Inc. (OTCQB: VIVXF) has announced a new customer in the Mexican dairy industry, procuring 220 kg/month of OxC-beta™ for three months starting September 2022.

This agreement highlights the ongoing expansion of OxC-beta™ in the dairy sector, which is vital for Avivagen due to its growth potential.

The customer, a family-owned business in Jalisco, has seen improved milk quality in trials using OxC-beta™, supporting Avivagen's goal of replacing antibiotics in livestock feed.

Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) announced a new order for four tonnes of its OxC-Beta™ Livestock product from a major Asian customer. This order aligns with previous shipments made in 2021, indicating strong demand amidst economic uncertainties. CEO Kym Anthony highlighted this order as a positive sign of the customer's economic recovery and the product's value in challenging times. OxC-Beta™ Livestock serves as a non-antibiotic growth promoter, promoting health and performance in livestock.

Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) announced a significant order of 1.2 tonnes of OxC-beta™ from AB Vista for use in Brazil's poultry and cattle trials. This order highlights the rising demand for non-antibiotic alternatives in livestock feeds. CEO Kym Anthony expressed optimism about the relationship with AB Vista, anticipating increased adoption of OxC-beta™ across the Americas. Brazil is a major feed producer, ranking third globally with 80.1 million metric tonnes in 2021, and AB Vista is the exclusive distributor for OxC-beta™ in key markets including the U.S., Brazil, and Thailand.